Vical Inc. (VICL)

0.68
0.13 16.51
NASDAQ : Health Technology
Prev Close 0.81
Open 0.79
Day Low/High 0.60 / 0.91
52 Wk Low/High 0.60 / 1.47
Volume 7.06M
Avg Volume 703.50K
Exchange NASDAQ
Shares Outstanding 22.84M
Market Cap 15.44M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition

SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition

NEW YORK, June 12, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Vical Incorporated ("VICL" or the "Company") (NASDAQ: VICL) in connection with the...

Vical Announces Restructuring To Focus Resources On HSV-2 And Antifungal Clinical Programs

Vical Announces Restructuring To Focus Resources On HSV-2 And Antifungal Clinical Programs

Vical expects to report that it ended 2017 with cash and investments of approximately $60 to $65 million

First Week of September 21st Options Trading For Vical

First Week of September 21st Options Trading For Vical

Investors in Vical Inc saw new options begin trading this week, for the September 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Vical Announces Completion Of The Phase 3 ASP0113 CMV Vaccine Trial

Vical Announces Completion Of The Phase 3 ASP0113 CMV Vaccine Trial

Astellas expects topline results in 1Q2018

Vical Reports First Quarter 2017 Financial Results

VL-2397 Data to be presented at ASM Microbe 2017 Conference in June

TheStreet Quant Rating: D (Sell)